Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANTX

ANTX - AN2 Therapeutics, Inc. Stock Price, Fair Value and News

3.33USD-0.37 (-10.00%)Market Closed
Watchlist

Market Summary

USD3.33-0.37
Market Closed
-10.00%

ANTX Alerts

  • CITADEL ADVISORS LLC reported owning 5.2% of ANTX [2024-02-14]
  • JANUS HENDERSON GROUP PLC reported owning 4.3% of ANTX [2024-02-12]
  • 3 major insider sales recently.

ANTX Stock Price

View Fullscreen

ANTX RSI Chart

ANTX Valuation

Market Cap

99.0M

Price/Earnings (Trailing)

-1.66

Price/Sales (Trailing)

85.42

Price/Free Cashflow

-2.26

ANTX Price/Sales (Trailing)

ANTX Profitability

Return on Equity

-42.94%

Return on Assets

-38.8%

Free Cashflow Yield

-44.28%

ANTX Fundamentals

ANTX Revenue

Revenue (TTM)

1.4M

ANTX Earnings

Earnings (TTM)

-59.7M

Earnings Growth (Yr)

-47.34%

Earnings Growth (Qtr)

-5.71%

Breaking Down ANTX Revenue

Last 7 days

-81.8%

Last 30 days

-82.6%

Last 90 days

-77.5%

Trailing 12 Months

-74.7%

How does ANTX drawdown profile look like?

ANTX Financial Health

Current Ratio

8.52

ANTX Investor Care

Shares Dilution (1Y)

53.29%

Diluted EPS (TTM)

-1.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202294.0K307.0K748.0K1.4M
202100069.0K

Tracking the Latest Insider Buys and Sells of AN2 Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 18, 2024
zakrzewski joseph s
sold
-1,911,410
19.1141
-100,000
-
Jan 16, 2024
aziz kabeer
sold
-312,573
19.65
-15,907
-
Jan 16, 2024
aziz kabeer
sold
-1,652,430
19.65
-84,093
-
Jan 16, 2024
adjuvant global health technology fund, l.p.
sold
-1,652,430
19.65
-84,093
-
Jan 16, 2024
adjuvant global health technology fund, l.p.
sold
-312,573
19.65
-15,907
-
Jan 12, 2024
readnour robin shane
sold
-31,228
21.915
-1,425
-
Jan 10, 2024
readnour robin shane
sold
-80,443
21.9251
-3,669
-
Jan 09, 2024
krause kevin michael
sold
-149,367
20.1385
-7,417
chief strategy officer
Jan 09, 2024
krause kevin michael
acquired
34,015
4.5861
7,417
chief strategy officer
Jan 02, 2024
krause kevin michael
acquired
1,084
0.42
2,583
chief strategy officer

1–10 of 50

Which funds bought or sold ANTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
new
-
3,840,000
3,840,000
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
39.17
4,437,260
10,174,400
0.30%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
1,218,030
1,218,030
-%
Feb 15, 2024
BARCLAYS PLC
added
1,295
856,000
907,000
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
812,920
812,920
-%
Feb 14, 2024
BVF INC/IL
unchanged
-
6,897,080
32,045,600
0.80%
Feb 14, 2024
VANGUARD GROUP INC
added
11.99
6,454,140
21,567,600
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-22.12
-5,834
757,966
0.02%
Feb 14, 2024
ExodusPoint Capital Management, LP
new
-
530,000
530,000
-%
Feb 14, 2024
RMB Capital Management, LLC
unchanged
-
202,605
941,352
0.03%

1–10 of 50

Are Funds Buying or Selling ANTX?

Are funds buying ANTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANTX
No. of Funds

Unveiling AN2 Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
ra capital management, l.p.
18.7%
5,551,295
SC 13G/A
Feb 14, 2024
citadel advisors llc
5.2%
6
SC 13G/A
Feb 14, 2024
pfizer inc
4.58%
1,362,499
SC 13G/A
Feb 13, 2024
easom eric
5.2%
1,572,170
SC 13G
Feb 12, 2024
janus henderson group plc
4.3%
1,279,975
SC 13G/A
Feb 09, 2024
adjuvant global health technology fund, l.p.
7.0%
2,080,051
SC 13G/A
Feb 09, 2024
tcg crossover gp i, llc
9.0%
2,678,209
SC 13G/A
Jul 25, 2023
tcg crossover gp i, llc
6.6%
1,289,320
SC 13G
Jul 05, 2023
janus henderson group plc
5.1%
1,000,076
SC 13G
Feb 14, 2023
ra capital management, l.p.
19.5%
3,773,517
SC 13G/A

Recent SEC filings of AN2 Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
8-K
Current Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Jan 19, 2024
4
Insider Trading
Jan 18, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to AN2 Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.4B
9.1B
-16.59% -47.80%
-9.64
3.66
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
19.5B
1.8B
-23.99% -31.71%
-44.27
10.66
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.44
7.22
15.05% 75.21%
13.5B
3.7B
-7.62% -26.87%
22.67
3.67
8.87% 75.42%
MID-CAP
7.9B
272.9M
-2.06% 34.31%
-13.08
29.05
141.38% 4.43%
5.9B
107.9M
-3.85% 226.12%
-9.53
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.44
6.46
23.54% 31.53%
3.9B
223.4M
8.92% 47.81%
-19.25
17.39
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.18
15.02
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.56
4.2
81.69% -7.29%
472.8M
1.0B
-9.17% -57.89%
-0.86
0.45
-43.15% 58.48%
179.5M
4.9M
-14.18% -58.18%
-1.09
36.72
-57.57% 50.48%
120.1M
881.7K
289.54% 381.25%
-2.53
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

AN2 Therapeutics, Inc. News

Latest updates
InvestorsObserver20 Feb 202401:09 pm
Seeking Alpha13 Feb 202408:00 am
Seeking Alpha12 Feb 202408:00 am
Simply Wall St21 Jan 202408:00 am
TradingView20 Jan 202408:00 am

AN2 Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue35.2%63046622827.0027.0025.0015.002.00
Operating Expenses6.0%12,47611,77010,3337,6837,5946,9324,9982,050
  S&GA Expenses11.4%3,7243,3423,6352,0501,7821,587898401
  R&D Expenses17.8%8,7527,4286,6985,6335,3125,3453,8501,649
Net Income-4.4%-11,842-11,339-10,120-7,655-7,545-6,943-5,007-2,048
Net Income Margin38.1%-30.32*-49.01*-105.09*-288.83*-312.22*---
Free Cashflow19.5%-7,638-9,487-9,595-6,742-8,993-4,691-5,257-1,543
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Assets55.5%15499.0091.0010311012012165.00
  Current Assets28.7%12698.0090.0099.0010711712060.00
    Cash Equivalents-20.1%33.0041.0027.0027.0029.0041.0083.0012.00
Liabilities32.9%15.0011.009.007.004.004.005.003.00
  Current Liabilities33.0%15.0011.009.007.004.004.005.003.00
Shareholder's Equity58.3%13988.0083.0095.00106116115-
  Retained Earnings-13.8%-137-120-105-89.72-77.88-66.54-56.42-47.38
  Additional Paid-In Capital32.5%277209188185184183172-
Shares Outstanding35.6%30.0022.0019.0019.0014.0011.003.003.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Cashflow From Operations8.0%-11,800-12,824-11,596-7,638-9,487-9,595-6,742-8,993-4,691-5,257-1,543
  Share Based Compensation11.6%2,1691,9432,0681,4721,2281,2424494333541798.00
Cashflow From Investing-893.0%-62,4627,87710,8876,055-2,317-39,48613,977----
Cashflow From Financing246.8%66,06619,050199--10.007,17863,187-969-240-79,744

ANTX Income Statement

2023-09-30
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 14,429$ 7,428$ 39,952$ 19,759
Research and development - related party 1,000 1,000
General and administrative3,7513,34210,8689,027
Total operating expenses18,18011,77050,82029,786
Loss from operations(18,180)(11,770)(50,820)(29,786)
Other income, net1,4734312,986672
Net loss(16,707)(11,339)(47,834)(29,114)
Accretion to redemption value and cumulative dividends on preferred stock   (1,820)
Net loss attributable to common stockholders$ (16,707)$ (11,339)$ (47,834)$ (30,934)
Net loss per share attributable to common stockholders, basic$ (0.65)$ (0.59)$ (2.22)$ (2.21)
Net loss per share attributable to common stockholders, diluted$ (0.65)$ (0.59)$ (2.22)$ (2.21)
Weighted-average number of shares used in computing net loss per share, basic25,645,42119,347,14821,532,53713,987,862
Weighted-average number of shares used in computing net loss per share, diluted25,645,42119,347,14821,532,53713,987,862
Other comprehensive loss:    
Unrealized gain (loss) on investments$ (3)$ (181)$ 252$ (514)
Comprehensive loss$ (16,710)$ (11,520)$ (47,582)$ (29,628)

ANTX Balance Sheet

2023-09-30
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 32,616$ 27,219
Short-term investments91,20268,840
Prepaid expenses and other current assets2,5912,509
Right-of-use asset, net 53
Total current assets126,40998,621
Long-term investments26,3563,219
Other assets, long-term1,043720
Total assets153,808102,560
Current liabilities:  
Accounts payable4,8772,122
Accrued compensation2,1962,168
Accrued liabilities6,7902,837
Other current liabilities973 
Operating lease liabilities 53
Options subject to repurchase, short-term36
Total current liabilities14,8397,186
Options subject to repurchase, long-term 2
Total liabilities14,8397,188
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.00001 par value; 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 29,741,445 and 19,402,658 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Additional paid-in capital276,648185,469
Accumulated other comprehensive loss(122)(374)
Accumulated deficit(137,557)(89,723)
Total stockholders' equity138,96995,372
Total liabilities and stockholders' equity$ 153,808$ 102,560
ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEwww.an2therapeutics.com
 EMPLOYEES35

AN2 Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for AN2 Therapeutics, Inc.? What does ANTX stand for in stocks?

ANTX is the stock ticker symbol of AN2 Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AN2 Therapeutics, Inc. (ANTX)?

As of Wed Feb 21 2024, market cap of AN2 Therapeutics, Inc. is 99.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers. The fair value of AN2 Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AN2 Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AN2 Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANTX is over valued or under valued. Whether AN2 Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact AN2 Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANTX.

What is AN2 Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, ANTX's PE ratio (Price to Earnings) is -1.66 and Price to Sales (PS) ratio is 85.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANTX PE ratio will change depending on the future growth rate expectations of investors.